World's First CAR-T Therapy for Solid Tumors Now Available at Jiahui International Cancer Center
In a significant breakthrough for cancer treatment, the Jiahui International Cancer Center (JICC) in Shanghai has received approval for Satri-cel (CT041, Kaileimei®), marking the first CAR-T cell therapy available for solid tumors in the world. This pioneering treatment is specifically indicated for patients suffering from Claudin18.2-positive, HER2-negative advanced adenocarcinomas of the stomach or gastroesophageal junction, who have not responded to at least two prior lines of therapy.
This approval, granted by the National Medical Products Administration (NMPA) of China, represents a historical milestone in oncology, expanding therapeutic options for patients worldwide. CAR-T therapy is renowned for its innovative approach, empowering the immune system to recognize and attack cancer cells. The approval of Satri-cel is not only a triumph for the JICC but also a significant advancement in the global oncological landscape.
As a leader in high-tech cancer care, JICC is strategically positioned to provide this groundbreaking treatment to patients both domestically and internationally. With a robust multidisciplinary cancer program and specialized services for international patients, the center has already treated CAR-T patients from various countries, reflecting the growing global interest in innovative cancer therapies available in China.
Dr. Linli Xuan, Head of the Medical Oncology Department at JICC, expressed her enthusiasm about this development: “The approval of Satri-cel is monumental for both patients and the global oncology community. The successful application of CAR-T therapy for solid tumors has been one of the foremost challenges in cancer medicine. This breakthrough not only brings renewed hope to patients with advanced gastric cancer but emphasizes China's increasing role in the development of groundbreaking cancer treatments.”
At the Jiahui International Cancer Center, the commitment to patient-centric care is paramount. They offer comprehensive oncology services, including medical oncology, surgical oncology, radiation therapy, precision medicine, and advanced cell therapies. The personalized treatment planning and dedicated international support services provided by the center ensure that patients from around the world have access to the latest advancements in cancer treatments.
In recent years, JICC has been at the forefront of treating CAR-T therapy patients, indicating a rising demand for access to international innovations in oncology. The approval of the world's first CAR-T therapy for solid tumors is anticipated to further accelerate the global demand for China’s rapidly evolving cancer treatment innovations.
Moreover, the approval opens doors for broader applications of CAR-T therapies, paving the way for future treatments that could benefit patients with various types of solid tumors. With the continuous evolution of therapy methodologies and advancements in research and technology, the landscape of cancer treatment is set to change significantly.
For those seeking information regarding international patient inquiries, JICC has streamlined communication through various channels including email and WhatsApp, ensuring timely assistance for prospective patients. The inauguration of SATRI-CEL signifies a transformative epoch in oncology, bridging the gap between advanced therapeutic strategies and patient accessibility.
In conclusion, Satri-cel's approval at Jiahui International Cancer Center exemplifies an essential step toward innovative cancer therapies that foster hope and improve outcomes for patients facing the challenges of solid tumors. This milestone not only highlights the capabilities of Jiahui but also represents a significant stride in cancer treatment on a global scale.
This approval, granted by the National Medical Products Administration (NMPA) of China, represents a historical milestone in oncology, expanding therapeutic options for patients worldwide. CAR-T therapy is renowned for its innovative approach, empowering the immune system to recognize and attack cancer cells. The approval of Satri-cel is not only a triumph for the JICC but also a significant advancement in the global oncological landscape.
As a leader in high-tech cancer care, JICC is strategically positioned to provide this groundbreaking treatment to patients both domestically and internationally. With a robust multidisciplinary cancer program and specialized services for international patients, the center has already treated CAR-T patients from various countries, reflecting the growing global interest in innovative cancer therapies available in China.
Dr. Linli Xuan, Head of the Medical Oncology Department at JICC, expressed her enthusiasm about this development: “The approval of Satri-cel is monumental for both patients and the global oncology community. The successful application of CAR-T therapy for solid tumors has been one of the foremost challenges in cancer medicine. This breakthrough not only brings renewed hope to patients with advanced gastric cancer but emphasizes China's increasing role in the development of groundbreaking cancer treatments.”
At the Jiahui International Cancer Center, the commitment to patient-centric care is paramount. They offer comprehensive oncology services, including medical oncology, surgical oncology, radiation therapy, precision medicine, and advanced cell therapies. The personalized treatment planning and dedicated international support services provided by the center ensure that patients from around the world have access to the latest advancements in cancer treatments.
In recent years, JICC has been at the forefront of treating CAR-T therapy patients, indicating a rising demand for access to international innovations in oncology. The approval of the world's first CAR-T therapy for solid tumors is anticipated to further accelerate the global demand for China’s rapidly evolving cancer treatment innovations.
Moreover, the approval opens doors for broader applications of CAR-T therapies, paving the way for future treatments that could benefit patients with various types of solid tumors. With the continuous evolution of therapy methodologies and advancements in research and technology, the landscape of cancer treatment is set to change significantly.
For those seeking information regarding international patient inquiries, JICC has streamlined communication through various channels including email and WhatsApp, ensuring timely assistance for prospective patients. The inauguration of SATRI-CEL signifies a transformative epoch in oncology, bridging the gap between advanced therapeutic strategies and patient accessibility.
In conclusion, Satri-cel's approval at Jiahui International Cancer Center exemplifies an essential step toward innovative cancer therapies that foster hope and improve outcomes for patients facing the challenges of solid tumors. This milestone not only highlights the capabilities of Jiahui but also represents a significant stride in cancer treatment on a global scale.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.